Nikhil Prasad Fact checked by:Thailand Medical News Team Jun 03, 2026 1 hour, 27 minutes ago
Medical News: Obstructive sleep apnea (OSA), a common but often overlooked sleep disorder affecting an estimated one billion people worldwide, may soon have a new treatment option that does not involve masks, machines, or surgery. Researchers have reported encouraging results from a large Phase 3 clinical trial showing that a once-nightly pill called AD109 significantly reduced sleep apnea severity and improved oxygen levels during sleep in patients who could not tolerate traditional CPAP therapy.
New Phase 3 trial results show that the experimental pill AD109 may offer a convenient alternative to CPAP for millions living with obstructive sleep apnea
The findings are generating excitement because AD109 is the first oral medication specifically designed to target the underlying biological mechanisms that cause airway collapse during sleep rather than simply managing symptoms.
A Major Unmet Need in Sleep Apnea Care
OSA occurs when the muscles that keep the upper airway open relax too much during sleep, causing repeated airway blockages. These interruptions can occur dozens of times per hour, leading to drops in blood oxygen levels, fragmented sleep, daytime fatigue, memory problems, cardiovascular complications, metabolic disorders, and an increased risk of early death.
The current gold-standard treatment is Continuous Positive Airway Pressure (CPAP), a machine that delivers pressurized air through a mask to prevent airway collapse. While CPAP is highly effective, many patients struggle with long-term use because of discomfort, inconvenience, or intolerance. Studies suggest that nearly half of patients discontinue CPAP within a year.
Recognizing this gap, researchers developed AD109, a combination of aroxybutynin and atomoxetine. Together, these medications help stimulate the nerves controlling upper airway muscles, keeping the throat open during sleep and reducing breathing interruptions.
Large Phase 3 Trial Delivers Strong Results
The Phase 3 SynAIRgy trial enrolled 646 adults with mild-to-severe OSA across 69 centers in the United States and Canada. Participants either could not tolerate CPAP or chose not to use it.
The study was led by researchers from the University of Pittsburgh Medical Center, working with multiple sleep medicine centers across North America.
Participants were randomly assigned to receive either AD109 or a placebo for 26 weeks in a double-blind, placebo-controlled trial.
Results showed that AD109 reduced the apnea-hypopnea index (AHI)—a key measure of breathing interruptions during sleep—by approximately 44.1 percent compared to a 17.6 percent reduction in the placebo group.
Even more impressive, more than 40 percent of participants moved into a less severe sleep apnea category, while 17.6 percent achieved complete disease control, meaning their AHI fell below five events per hour, a level considered normal.
Researchers also found significant improvements in oxygen-related measures. The oxygen desaturation index, which tracks drops in blood oxygen during sleep, improved substantially. Patients also exper
ienced reductions in hypoxic burden, a measure reflecting the frequency, depth, and duration of oxygen deprivation episodes that have been linked to heart disease and premature mortality.
Benefits Seen Across Different Patient Groups
One of the most important findings was the consistency of the results. AD109 demonstrated effectiveness regardless of sex, body weight, obesity status, or baseline disease severity. This broad response suggests the medication could potentially help a much wider population than some existing treatments that work best only in specific patient groups.
Researchers noted that the drug's effectiveness appeared rapidly, with meaningful improvements observed as early as four weeks after treatment began.
Importantly, the benefits were not primarily driven by weight loss or changes in sleep patterns, strengthening evidence that the medication is directly targeting the neuromuscular dysfunction responsible for airway collapse.
Safety and Side Effects
Like all medications, AD109 was associated with side effects. The most commonly reported adverse events included dry mouth, nausea, insomnia, and urinary hesitation. Most side effects were mild and occurred early in treatment.
However, approximately 21.2 percent of participants discontinued the medication because of side effects, compared to 3.1 percent in the placebo group.
Researchers noted that many discontinuations occurred shortly after treatment began, suggesting that patients who tolerate the initial treatment period may have better long-term success.
Importantly, no serious treatment-related adverse events were reported during the trial.
Fast Track Status and Regulatory Progress
The promising results have attracted regulatory attention. AD109 has already received Fast Track designation from the U.S. FDA, a status granted to therapies addressing significant unmet medical needs.
Its developer, Apnimed, has submitted a New Drug Application to the FDA and is awaiting review. If accepted, a regulatory decision could potentially arrive in early 2027.
This
Medical News report highlights what many experts consider one of the most significant advances in sleep apnea treatment in decades.
Conclusion
The SynAIRgy trial suggests that AD109 could become the first widely available oral medication that directly addresses the neuromuscular root causes of obstructive sleep apnea. While CPAP remains the most effective therapy for many patients, millions either cannot tolerate it or stop using it altogether. AD109 demonstrated meaningful reductions in airway obstruction, improved oxygen levels, and disease control across a diverse patient population. Although side effects remain a concern for some individuals, the overall findings indicate that this once-nightly pill may eventually offer a simpler and more acceptable alternative for patients struggling with current treatment options.
The study findings were published in the peer reviewed American Journal of Respiratory and Critical Care Medicine.
https://academic.oup.com/ajrccm/advance-article/doi/10.1093/ajrccm/aamag215/8680221
For the latest on Sleep Apnea, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
